NBIX - ニュ―ロクライン・バイオサイエンシズ (Neurocrine Biosciences Inc.)

NBIXのニュース

   Neurocrine Biosciences Announces Repurchase of Convertible Notes  2020/11/19 13:00:00 PR Newswire
SAN DIEGO, Nov. 19, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the Company has entered into separate, privately negotiated transactions (the "Agreements") with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the "2024…
   Neurocrine Biosciences Reports Third Quarter 2020 Financial Results  2020/11/09 21:01:00 Benzinga
SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 2020 financial expense guidance. "Our focus remains on helping as many patients with tardive dyskinesia as possible and we are adapting to the challenges posed by the pandemic, including the slow recovery of in-person visits with psychiatrists. We are encouraged by recent trends and remain confident in the intermediate and long-term opportunity of INGREZZA to help many more patients with tardive dyskinesia," said Kevin Gorman , Ph.D., Chief Executive Officer of Neurocrine Biosciences. "We are pleased to expand our reach with neurologists with the addition of ONGENTYS to our movement disorder portfolio and continue to advance our development programs focused on neurological, endocrine and psychiatric disorders." Financial Highlights Three Months Ended September 30, Nine Months Ended September 30, (unaudited, in millions, except per share data) 2020 2019 2020 2019 Revenues: Product sales, net $ 254.
   Neurocrine Biosciences to Present at Upcoming Healthcare Conferences  2020/11/09 14:00:00 PR Newswire
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Kevin Gorman, Chief Executive Officer, and Kyle Gano, Chief Business Development and Strategy…
   Neurocrine Biosciences Q3 2020 Earnings Preview (NASDAQ:NBIX)  2020/11/08 17:02:31 Seeking Alpha
Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to announce Q3 earnings results on Monday, November 9th, after market close. The consensus EPS Estimate i
   Biogen, UnitedHealth: 5 Top Stock Gainers for Wednesday  2020/11/04 18:03:11 The Street
Super Micro Computer, Biogen, Neurocrine Biosciences, Supernus Pharmaceuticals and UnitedHealth.
   Neurocrine Biosciences Announces Repurchase of Convertible Notes  2020/11/19 13:00:00 PR Newswire
SAN DIEGO, Nov. 19, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the Company has entered into separate, privately negotiated transactions (the "Agreements") with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the "2024…
   Neurocrine Biosciences Reports Third Quarter 2020 Financial Results  2020/11/09 21:01:00 Benzinga
SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 2020 financial expense guidance. "Our focus remains on helping as many patients with tardive dyskinesia as possible and we are adapting to the challenges posed by the pandemic, including the slow recovery of in-person visits with psychiatrists. We are encouraged by recent trends and remain confident in the intermediate and long-term opportunity of INGREZZA to help many more patients with tardive dyskinesia," said Kevin Gorman , Ph.D., Chief Executive Officer of Neurocrine Biosciences. "We are pleased to expand our reach with neurologists with the addition of ONGENTYS to our movement disorder portfolio and continue to advance our development programs focused on neurological, endocrine and psychiatric disorders." Financial Highlights Three Months Ended September 30, Nine Months Ended September 30, (unaudited, in millions, except per share data) 2020 2019 2020 2019 Revenues: Product sales, net $ 254.
   Neurocrine Biosciences to Present at Upcoming Healthcare Conferences  2020/11/09 14:00:00 PR Newswire
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Kevin Gorman, Chief Executive Officer, and Kyle Gano, Chief Business Development and Strategy…
   Neurocrine Biosciences Q3 2020 Earnings Preview (NASDAQ:NBIX)  2020/11/08 17:02:31 Seeking Alpha
Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to announce Q3 earnings results on Monday, November 9th, after market close. The consensus EPS Estimate i
   Biogen, UnitedHealth: 5 Top Stock Gainers for Wednesday  2020/11/04 18:03:11 The Street
Super Micro Computer, Biogen, Neurocrine Biosciences, Supernus Pharmaceuticals and UnitedHealth.
   Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020  2020/09/11 15:34:00 PR Newswire
SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from two post-hoc analyses of Phase III data, demonstrating that once-daily ONGENTYS® (opicapone) capsules decreased "off" time and increased "on" time without troublesome…
   Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference  2020/09/08 20:01:00 PR Newswire
SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 18th Annual Global Healthcare Conference at 1:30 p.m. ET on Monday, September 14, 2020. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial…
   Looking Into Neurocrine Biosciences's Return On Capital Employed  2020/08/28 10:11:00 Benzinga
Looking at Q2, Neurocrine Biosciences (NASDAQ: NBIX) earned $76.60 million, a 30.05% increase from the preceding quarter. Neurocrine Biosciences also posted …
   Neurocrine Biosciences und Takeda kündigen Zusammenarbeit bei der Entwicklung und Vermarktung möglicher Therapien für psychische Störungen an  2020/06/16 21:25:00 Business Wire
SAN DIEGO und OSAKA, Japan--(BUSINESS WIRE)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX) und die Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda”) gaben heute eine strategische Zusammenarbeit bei der Entwicklung und Vermarktung von Wirkstoffen aus der Takeda-Pipeline der im frühen bis mittleren Entwicklungsstadium befindlichen Psychatrie-Medikamente bekannt. Im Rahmen dieser Kooperation gewährte Takeda Neurocrine Biosciences insbesondere eine Exklusivlizenz für sieben Pipeline
   Neurocrine Biosciences et Takeda annoncent une collaboration pour le développement et la mise sur le marché de thérapies potentielles contre les troubles psychiatriques  2020/06/16 20:04:00 Business Wire
SAN DIEGO & OSAKA, Japon--(BUSINESS WIRE)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX) et Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (« Takeda ») annoncent ce jour une collaboration stratégique pour le développement et la mise sur le marché de composés en phase initiale et intermédiaire du pipeline psychiatrique de Takeda. Takeda a accordé une licence exclusive à Neurocrine Biosciences pour sept programmes de pipeline, dont trois actifs en phase clinique pour la schizophrénie, la

calendar